2019 American Transplant Congress
Clinical Outcomes of Patients with Portal Vein Tumor Thrombi after Living Donor Liver Transplantation
Surgery, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea, Republic of
*Purpose: Patient selection criteria for living donor liver transplantation(LDLT) with hepatocellular carcinoma are generally wider than those for deceased donor liver transplantation. It is widely…2019 American Transplant Congress
Peri-Operative Basiliximab is Not Associated with Post-Transplant Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients
*Purpose: The optimal immunosuppression for liver transplant recipients (LTR) with hepatocellular carcinoma (HCC) is unknown. Basiliximab, an interleukin-2 receptor antagonist (IL-2RA), confers immunosuppression for LTR…2018 American Transplant Congress
Prognostic Value and Biological Significances of Five Long Non-Coding RNAs in Hepatocellular Carcinoma
Objectives Increasing evidence suggests that long non-coding RNA (lncRNA) plays a vital role in metastasis and development in hepatocellular carcinoma (HCC). Tumor progression severely affect…2018 American Transplant Congress
Small-for-Size Grafts Increase Recurrence of Hepatocellular Carcinoma in Liver Transplantation beyond Milan Criteria
Center for Liver Cancer, National Cancer Center, Goyang, Korea.
BACKGROUND: Living donor liver transplantation (LDLT) has been reported to have high rates of hepatocellular carcinoma (HCC) recurrence compared to deceased donor liver transplant (DDLT).…2018 American Transplant Congress
TP53 Mutations Lead to Increased Transcription of Circular RNAs in Exosomes Enhancing Tumor Invasiveness in Hepatocellular Carcinoma Bases on Bioinformatics Analysis
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Objective Increasing evidence suggests that cicular RNAs play an important role in tumor. A recent study found the enrichment of cicular RNAs in HCC derived…2018 American Transplant Congress
Impact of Donor Age on Outcomes after Living Donor Liver Transplantation
Background: Liver transplantation (LT) is a curative treatment for decompensated cirrhosis and fulminant hepatitis. Although not a few patients received LT with marginal donor livers…2018 American Transplant Congress
Validating MORAL in Living Donor Liver Transplantation for Hepatocellular Carcinoma
The “Model of Recurrence after Liver Transplant” (MORAL) study has identified certain pre and post operative variables that have significant impact on recurrence free survival…2018 American Transplant Congress
Living Donor Liver Transplantation for Hepatocellular Carcinoma beyond UCSF Criteria: Can We Achieve a Modest Long-Term Survival? A Single Center Retrospective Analysis of Using Extended Criteria
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan.
Milan's criteria were universally validated for LT in HCC patients and, were accepted as allocation criteria of UNOS in 2001 & Eurotransplantation in 2006. However,…2018 American Transplant Congress
Prediction of Hepatocellular Carcinoma Recurrence Following Liver Transplantation Using Combined Differential Gene Expression, Copy Number Variation and Somatic Mutation Analysis
Liver allocation for transplant candidates with hepatocellular carcinoma is limited by OPTN policy to patients whose tumors remain within size limits defined by Milan criteria.…2018 American Transplant Congress
Tregs Expression Predicts Prognosis in Patients with Hepatocellular Carcinoma
New therapeutic strategies are needed to improve the survival of patients with hepatocellular carcinoma (HCC), the third in overall global cancer-related mortality. T regulatory cells…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 23
- Next Page »